Provider: Wright Reports
Swedish Orphan Biovitrum publ AB: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Swedish Orphan Biovitrum AB Publ Files for Kineret Label to Include CAPS
Swedish Orphan Biovitrum AB Publ announced that it has filed an application for an European Union (EU) Marketing Authorization with the European Medicines Agency (EMA) for Kineret (anakinra) for the indication of cryopyrin associated periodic syndromes (CAPS). The filing is based on positive safety and efficacy outcome data from a long-term treatment study in children and adults with neonatal-onset multisystem inflammatory disease (NOMID), the most severe form of CAPS. The EMA filing follows the filing for Kineret for NOMID with the United States Food and Drug Administration (FDA) in July 2012, which has been granted priority review with an expected approval date of December 25, 2012.
Latest Developments for Swedish Orphan Biovitrum publ AB
- Swedish Orphan Biovitrum publ AB maintains FY 2014 financial guidance
- FDA approves Swedish Orphan Biovitrum and Biogen Idec Eloctate
- Swedish Orphan Biovitrum elects Ernst & Young as auditor
- Swedish Orphan Biovitrum and Biogen Idec announce positive efficacy and safety results from phase-3 paediatric study of investigational therapy Eloctate for haemophilia A
- Share this
- Digg this